The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Smoking damages the blood vessels in the eyes, which over time increases the risk for several complications, including ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.